
Quarterly report 2025-Q3
added 11-05-2025
Foghorn Therapeutics Net Debt 2011-2026 | FHTX
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Foghorn Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -18.3 M | -35.3 M | -707 K | -42.8 M | -69.2 M | 1.65 M | -33 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.65 M | -69.2 M | -28.2 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Adagene
ADAG
|
-71 M | $ 1.65 | 7.91 % | $ 92.9 M | ||
|
AstraZeneca PLC
AZN
|
9.86 B | $ 93.52 | -1.2 % | $ 96.9 B | ||
|
Autolus Therapeutics plc
AUTL
|
-187 M | $ 1.52 | -16.3 % | $ 388 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.59 | 1.99 % | $ 8.64 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
Biogen
BIIB
|
4.01 B | $ 184.48 | -1.67 % | $ 26.9 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
BioNTech SE
BNTX
|
-973 M | $ 102.17 | 2.32 % | $ 27.2 B | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 4.25 | 1.67 % | $ 9.25 B | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Ascendis Pharma A/S
ASND
|
-195 M | $ 207.49 | 2.22 % | $ 5 B | ||
|
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | ||
|
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | ||
|
Catalyst Biosciences
CBIO
|
-33.1 M | $ 10.84 | 0.46 % | $ 714 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-119 M | - | -15.15 % | $ 60.3 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
-121 M | $ 37.35 | -0.4 % | $ 3.86 B | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Catalyst Pharmaceuticals
CPRX
|
-514 M | $ 23.18 | 2.02 % | $ 2.75 B | ||
|
AIkido Pharma
AIKI
|
-1.04 M | - | 1.93 % | $ 17.4 M | ||
|
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | ||
|
Celldex Therapeutics
CLDX
|
-24.5 M | $ 25.59 | -6.54 % | $ 1.65 M | ||
|
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
Cellectis S.A.
CLLS
|
-206 M | $ 4.22 | -4.2 % | $ 116 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | ||
|
Amphastar Pharmaceuticals
AMPH
|
469 M | $ 29.43 | 6.09 % | $ 1.43 B | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Brickell Biotech
BBI
|
-29.7 M | - | -5.38 % | $ 6.06 M | ||
|
Burford Capital Limited
BUR
|
-135 M | $ 9.66 | 2.28 % | $ 1.53 B | ||
|
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | ||
|
Arena Pharmaceuticals
ARNA
|
-25.4 M | - | -6.81 % | $ 3.04 B | ||
|
Arrowhead Pharmaceuticals
ARWR
|
-115 M | $ 66.05 | 2.3 % | $ 8.83 B | ||
|
Athersys
ATHX
|
-27.6 M | - | 3.77 % | $ 22.4 M | ||
|
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
-213 M | $ 55.11 | 3.49 % | $ 4.45 B | ||
|
Abeona Therapeutics
ABEO
|
-9.07 M | $ 5.14 | -1.06 % | $ 110 M | ||
|
CRISPR Therapeutics AG
CRSP
|
-74.6 M | $ 55.17 | 2.47 % | $ 4.65 B | ||
|
AVROBIO
AVRO
|
-76.6 M | - | 1083.1 % | $ 745 M | ||
|
Axon Enterprise
AXON
|
-404 M | $ 632.29 | 0.09 % | $ 47.9 B | ||
|
ADiTx Therapeutics
ADTX
|
287 K | $ 0.81 | 1.96 % | $ 10.7 K | ||
|
Aytu BioScience
AYTU
|
-19.9 M | $ 2.7 | 2.27 % | $ 17 M |